JP2022512905A5 - - Google Patents
Info
- Publication number
- JP2022512905A5 JP2022512905A5 JP2021523957A JP2021523957A JP2022512905A5 JP 2022512905 A5 JP2022512905 A5 JP 2022512905A5 JP 2021523957 A JP2021523957 A JP 2021523957A JP 2021523957 A JP2021523957 A JP 2021523957A JP 2022512905 A5 JP2022512905 A5 JP 2022512905A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- nucleotide sequence
- antibody
- virus
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024188854A JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203993.3 | 2018-11-01 | ||
| EP18203993 | 2018-11-01 | ||
| PCT/EP2019/080004 WO2020089474A1 (en) | 2018-11-01 | 2019-11-01 | Novel antagonistic anti tnfr2 antibody molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188854A Division JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512905A JP2022512905A (ja) | 2022-02-07 |
| JP2022512905A5 true JP2022512905A5 (enExample) | 2022-10-26 |
| JP7646542B2 JP7646542B2 (ja) | 2025-03-17 |
Family
ID=64109794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523957A Active JP7646542B2 (ja) | 2018-11-01 | 2019-11-01 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
| JP2024188854A Withdrawn JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188854A Withdrawn JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12441805B2 (enExample) |
| EP (1) | EP3873936A1 (enExample) |
| JP (2) | JP7646542B2 (enExample) |
| KR (1) | KR20210087029A (enExample) |
| CN (3) | CN118667024A (enExample) |
| AU (1) | AU2019372184A1 (enExample) |
| BR (1) | BR112021007995A2 (enExample) |
| CA (1) | CA3117864A1 (enExample) |
| IL (1) | IL282715A (enExample) |
| MX (1) | MX2021005150A (enExample) |
| WO (1) | WO2020089474A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI878554B (zh) | 2020-06-12 | 2025-04-01 | 大陸商南京維立志博生物科技股份有限公司 | 結合ｔｎｆｒ２的抗體及其用途 |
| US20240043551A1 (en) * | 2020-12-11 | 2024-02-08 | Adlai Nortye Biopharma Co., Ltd. | Anti-tnfr2 antibody and application thereof |
| TW202235434A (zh) * | 2020-12-31 | 2022-09-16 | 美商諾瓦拉克生物醫療有限公司 | 針對tnfr2之抗體及其用途 |
| CN117425675A (zh) * | 2020-12-31 | 2024-01-19 | 新石生物制药有限公司 | Tnfr2抗体及其用途 |
| EP4286411A4 (en) * | 2021-01-29 | 2025-06-25 | Shandong Simcere Biopharmaceutical Co., Ltd. | Humanized antibody against tnfr2 and use thereof |
| EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
| CN119591711B (zh) * | 2024-11-12 | 2026-01-13 | 澳门大学 | 一种抑制性tnfr2单域抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| CN1997667A (zh) * | 2004-05-10 | 2007-07-11 | 宏观基因有限公司 | 人源化FcγRⅡB特异性抗体及其使用方法 |
| EP2371390A3 (en) | 2004-10-08 | 2013-03-13 | Domantis Limited | Antagonists and methods of use therefor |
| TWI687439B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| EP3936137A1 (en) | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| EP3973980A1 (en) * | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
| CN115043943A (zh) * | 2015-05-15 | 2022-09-13 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
| US20190135929A1 (en) | 2015-08-28 | 2019-05-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| AU2016317915B2 (en) * | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| CA3004830A1 (en) * | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| US11859002B2 (en) | 2016-05-13 | 2024-01-02 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor 2 antibodies |
| EP3475301B1 (en) | 2016-06-22 | 2023-01-04 | Université Paris-Est Créteil Val de Marne | Prevention or treatment of hematologic malignancy relapse using a tnfr2 antagonist |
-
2019
- 2019-11-01 JP JP2021523957A patent/JP7646542B2/ja active Active
- 2019-11-01 MX MX2021005150A patent/MX2021005150A/es unknown
- 2019-11-01 WO PCT/EP2019/080004 patent/WO2020089474A1/en not_active Ceased
- 2019-11-01 US US17/290,352 patent/US12441805B2/en active Active
- 2019-11-01 BR BR112021007995-5A patent/BR112021007995A2/pt unknown
- 2019-11-01 CN CN202411004493.6A patent/CN118667024A/zh active Pending
- 2019-11-01 CA CA3117864A patent/CA3117864A1/en active Pending
- 2019-11-01 AU AU2019372184A patent/AU2019372184A1/en active Pending
- 2019-11-01 EP EP19805901.6A patent/EP3873936A1/en active Pending
- 2019-11-01 KR KR1020217012926A patent/KR20210087029A/ko not_active Ceased
- 2019-11-01 CN CN201980071097.6A patent/CN112955469B/zh active Active
- 2019-11-01 CN CN202411004492.1A patent/CN118702818A/zh active Pending
-
2021
- 2021-04-27 IL IL282715A patent/IL282715A/en unknown
-
2024
- 2024-10-28 JP JP2024188854A patent/JP2025022888A/ja not_active Withdrawn
-
2025
- 2025-09-04 US US19/318,835 patent/US20250388690A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512905A5 (enExample) | ||
| US12258411B2 (en) | Anti-CCR8 antibodies and uses thereof | |
| JP2022514179A5 (enExample) | ||
| JP7257364B2 (ja) | 抗ｃｄ１３７抗体 | |
| JP7366543B2 (ja) | Ｂｃｍａ結合分子及びその使用方法 | |
| KR102340832B1 (ko) | 항 pd-1 항체 및 그의 용도 | |
| KR102907326B1 (ko) | Cd137을 표적화하는 항체 및 이의 사용 방법 | |
| JP2020532965A (ja) | 抗ｃｄ１３７分子及びその使用 | |
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| KR102678252B1 (ko) | 재조합 이중특이적 항체 | |
| JP7535060B2 (ja) | 抗ｃｄ４０抗体およびその使用 | |
| CN115210261A (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| JP2025020172A (ja) | Ｃｄ１３７を標的とする抗体およびその使用方法 | |
| JP2018506296A (ja) | Ｉｌ−１７ｃに対する抗体 | |
| EP3636320A1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| CN116234909A (zh) | Cd40激动剂抗体和使用方法 | |
| WO2019072566A1 (en) | COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER | |
| RU2021115554A (ru) | Новые молекулы антагонистических анти-tnfr2-антител | |
| RU2021115563A (ru) | Новые молекулы агонистических анти-tnfr2 антител | |
| CN113166264B (zh) | 一种分离的抗原结合蛋白及其用途 | |
| CN118324910A (zh) | Ccr8抗体的应用 | |
| EA045980B1 (ru) | Антитела против рецептора полиовируса (pvr) и их применение | |
| JP2025532758A (ja) | 癌の治療における使用のためのｂｔｎ３ａ活性化抗体、ｂｃｌ２阻害剤及び低メチル化剤の併用 | |
| HK40117648A (zh) | Il-18bp拮抗剂抗体及其在癌症治疗中的单一疗法和组合疗法中的用途 | |
| HK40087544A (zh) | 改善与静脉内施用有关的抗体耐受性 |